MarketPeel
Insider Trading Intelligence
Pricing
…
EC

Eliana Clark

NTLA
EVP, CHIEF TECHNICAL OFFICER · INTELLIA THERAPEUTICS, INC. · CIK 0001914448
FILING MIX · LIFETIME44%/56%
BUYS
12
SELLS
15
TOTAL VALUE
$737.1K
COMPANIES
1
ACTIVE SINCE
Mar 2022
HOLDINGS NOW
93,864
AVG SELL PX
$20.83
TRADE KIND
SHOWING 27 / 27
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
14 backtested trades · 8 horizons · 9 pending
Forward-return performance of every backtestable P/S trade by Eliana Clark, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d14+57.14%+1.02%+0.56%+0.45%-3.10%—
14d14+57.14%-1.38%+0.71%-2.10%-9.00%—
30d14+57.14%-0.40%+2.61%-3.01%-6.86%—
60d14+50.00%+0.82%+2.92%-2.10%-2.16%—
90d14+71.43%-6.00%+2.90%-8.67%-21.55%—
180d14(1 pending)+69.23%-7.53%+10.77%-18.30%-25.11%—
1y14(2 pending)+83.33%-23.14%+20.63%-43.77%-45.42%—
2y14(6 pending)+100.00%-61.21%+46.58%-107.79%-116.81%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
NTLA · 93,864 shares · as of Mar 2, 2026
024,01248,02472,03696,0482023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 12 buys / 15 sellsCOVERAGE · 17 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Technical Officer
607$13.78$8.4K93,864Mar 2, 2026Mar 3, 2026 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
10,505——10,505Mar 1, 2026Mar 3, 2026 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
7,353——94,471Mar 1, 2026Mar 3, 2026 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Technical Officer
9,515$9.21$87.6K87,118Jan 5, 2026Jan 7, 2026 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Technical Officer
1,022$9.82$10.0K95,369Jul 1, 2025Jul 3, 2025 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Technical Officer
679$8.99$6.1K95,369Mar 4, 2025Mar 4, 2025 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
32,000——96,048Mar 1, 2025Mar 4, 2025 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
45,714——45,714Mar 1, 2025Mar 4, 2025 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Technical Officer
7,422$12.18$90.4K64,048Jan 3, 2025Jan 6, 2025 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Technical Officer
556$12.03$6.7K71,470Jan 2, 2025Jan 6, 2025 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Technical Officer
405$22.93$9.3K71,470Jul 1, 2024Jul 3, 2024 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Technical Officer
605$32.99$20.0K71,470Mar 4, 2024Mar 5, 2024 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
45,072——45,072Mar 1, 2024Mar 5, 2024 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
31,230——72,075Mar 1, 2024Mar 5, 2024 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Technical Officer
4,301$29.46$126.7K40,845Jan 3, 2024Jan 5, 2024 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Technical Officer
307$30.12$9.2K45,146Jan 3, 2024Jan 5, 2024 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Technical Officer
5,000——57,750Jun 20, 2023Jun 22, 2023 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,000$45.00$225.0K45,146Jun 20, 2023Jun 22, 2023 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASE
EVP, Chief Technical Officer
5,000$12.27$61.4K50,146Jun 20, 2023Jun 22, 2023 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
24,539——39,012Mar 1, 2023Mar 3, 2023 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
34,674——34,674Mar 1, 2023Mar 3, 2023 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
6,134——45,146Mar 1, 2023Mar 3, 2023 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Technical Officer
1,692$37.21$63.0K14,473Jan 4, 2023Jan 6, 2023 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Technical Officer
231$34.48$8.0K16,165Jan 3, 2023Jan 6, 2023 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Technical Officer
105$51.74$5.4K16,165Jul 1, 2022Jan 6, 2023 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
10,527——16,165Mar 1, 2022Mar 7, 2022 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,395——15,395Mar 1, 2022Mar 7, 2022 ↗View →
Other insiders · NTLA
Loading peer insiders…
About this filer
CIK 0001914448
ROLE
EVP, Chief Technical Officer
PRIMARY
NTLA
COMPANIES
1
ACTIVE SINCE
Mar 2022
MARKETPEEL · /INSIDER/0001914448DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback